Company Analysis
Sign in

argenx SE (ARGX)

Nasdaq: ARGX · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2017
Full chart Alerts Compare
Grade6.3
◀ Past 5.5● Present 6.3▶ Future 7.1
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

10 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to argenx SE’s names, not what it holds today.

Patents granted
10
10 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
1
since 2001, to Dec 31, 2025
Names they are printed under
1
its own name
By yearGrantedApplications published
'15'16'17'18'19
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name1 counted
ARGEN-X N.V. its own name
NL, as the owner printed on each patent. 1 more under the same name are not counted (printed in BE)
10 granted
1 published
Names not counted (2)
ARGENX SE
Most of its patents print BE; this name counts in NL. 0 granted and 65 published under it are not counted.
ARGENX SE
Most of its patents print BE; this name counts in NL. 28 granted and 14 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jan 22, 201910,183,995IL-6 binding moleculesPharmaceuticalsARGEN-X N.V.
Mar 27, 20189,926,364Chimeric human-llama antigens and methods of useBiotechnologyARGEN-X N.V.
Feb 6, 20189,884,917Anti c-Met antibodiesPharmaceuticalsARGEN-X N.V.
Sep 19, 20179,765,149Antibodies to CD70PharmaceuticalsARGEN-X N.V.
Sep 19, 20179,765,148Antibodies to CD70PharmaceuticalsARGEN-X N.V.
Jun 27, 20179,688,774Anti c-Met antibodiesPharmaceuticalsARGEN-X N.V.
Jun 27, 20179,688,773C-Met antibody combinationsPharmaceuticalsARGEN-X N.V.
Apr 25, 20179,631,027Anti c-Met antibodiesPharmaceuticalsARGEN-X N.V.
Jan 10, 20179,540,437Humanized antibodiesBiotechnologyARGEN-X N.V.
Apr 19, 20169,315,576Antigen binding polypeptidesBiotechnologyARGEN-X N.V.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 23, 20152015/0203840METHOD FOR PRODUCING ANTIBODY MOLECULES HAVING INTER-SPECIES, INTRA-TARGET CROSS-REACTIVITYBiotechnologyARGEN-X N.V.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ARGX · research, not advice